AdultTreatment-naive or treatment-experienced integrase strand transfer inhibitor (INSTI)-naive 50 mg once daily. Treatment-naive or treatment-experienced INSTI-naive when co-administered w/ certain UGT1A or CYP3A inducers, & INSTI-experienced w/ certain INSTI-associated resistance substitution or clinically suspected INSTI resistance 50 mg bid. Childn ≥40 kg 50 mg once daily, 30 kg-40 kg 35 mg once daily.
Discontinue use if hypersensitivity reactions occur. Monitor clinical status including liver aminotransferases. Increased risk of development of transaminase elevations in patients w/ hepatitis B or C. Monitor for hepatotoxicity during therapy especially in patients w/ underlying hepatic disease. Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement & "cushingoid appearance". Immune reconstitution syndrome; autoimmune disorders (eg, Graves' disease, polymyositis & Guillain-Barre syndrome). Not recommended during lactation. Pregnancy.
Sign Out
